Regeneus

27/01/2022

Regeneus scientists Flyn McKinnirey, Brian Saputro and Grace Crosland can be seen performing flow cytometry to characterise Progenza™ Medicinal Signaling Cells. Learn more about the science behind Regeneus: https://buff.ly/3fD9L4r

20/01/2022

Pictured: Regeneus R&D Scientist Brian Saputro performing quality control on Progenza™ by taking samples for cytokine profile analysis. Cytokines are one of the protein groups our Medicinal Signaling Cells secrete that produce the disease modifying and therapeutic effect to patients. Learn more about the science behind Regeneus: https://buff.ly/3fD9L4r

23/12/2021

From the team here at Regeneus, we wish you a very happy, safe and well-deserved break this holiday season. To our investors, thank you for your continued support as we progress toward commercialisation. We look forward to sharing more positive updates in the New Year.

16/12/2021

There is a strong focus on Australia's regenerative medicine future in the latest edition of AusBiotech's Australasian Biotechnology Journal. Read pages 60-62 for a taste of why we are so excited to be part of the sector that's developing ground-breaking therapies for patients in Australia, and worldwide: https://buff.ly/3pYmsMb

14/12/2021

Regeneus R&D Manager Flyn McKinnirey has an unwavering commitment to investigating new and innovative ways to enhance our products and deliver the best possible patient outcome. Learn more about Flyn's role at Regeneus: https://buff.ly/3pRJAM1

09/12/2021

Behind the scenes at Regeneus, our scientists perform regular cell counts on our lead technology platform Progenza™ to ensure the quality of the product. Read more about Progenza™: https://buff.ly/3lLWqtY

07/12/2021

Published in the world's leading multidisciplinary science journal, Nature Scientific Reports, Regeneus R&D Manager Flyn McKinnirey’s paper: ‘Immune modulation via adipose derived Mesenchymal Stem cells is driven by donor s*x in vitro’ uncovers the difference in potency and functionality between female and male adipose derived MSCs. Hear from Flyn how this will help inform donor choice for the most efficacious cellular therapies. Read: https://buff.ly/3EvwhXL

26/11/2021

Here pictured is Regeneus Research Scientist Chrys Maoudis conducting an immunoassay on the bioactive secretome that is used in Progenza™ and Sygenus. The immunoassay tests for specific protein amounts in the secretome of our Medicinal Signaling Cells, which we measure to ensure batch to batch consistency of secretome content (cytokines, chemokines and enzymes), which hold the therapeutic effect.
Learn more about the science behind Regeneus' technologies: https://regeneus.com.au/science/

19/11/2021

Australia's regenerative medicine landscape is rapidly evolving with the opportunity to become a global leader in the sector. The latest edition of AusBiotech's Australasian Biotechnology Journal says success of the regenerative medicine sector in Australia could be worth at least $6 billion in annual revenue, and the market can prepare for groundbreaking therapies targeting a wide range of conditions with unmet clinical needs.

We are proud to be part of this cohort at Regeneus and look forward to growing with the industry. Read more: https://www.ausbiotech.org/documents/version/660

11/11/2021

Meet Dr. Cindy Shu! Dr. Shu joins Regeneus from University of Sydney's Kolling Institute as part of the MTPConnect REDI Fellowship Grant program.

In the latest of Regeneus' Q&A series, we learn about Dr. Shu's expertise in osteoarthritis pathophysiology, animal models and immune cell analysis, and how this will support Regeneus' Progenza™ clinical program into 2022. Read here: https://regeneus.com.au/news/qa-with-dr-cindy-shu-redi-fellow/

05/11/2021

If you missed Regeneus’ investor session this week, you can catch up below to hear CEO Karolis Rosickas, joined by Dr Charlotte Morgan and Dr Sinead Blaber, provide an update on the Company's progress with its lead platform technology Progenza™, including its collaboration with Kyocera in Japan, partnership with the Defence Australia for Sygenus, and ongoing strategy.

Regeneus CEO Karolis Rosickas hosted a webinar and Q&A with investors on Thursday 4 November. During the session, Karolis provided an update on the Company's...

03/11/2021

Last chance to register! Regeneus CEO Karolis Rosickas is hosting a webinar tomorrow, 4 November at 2pm AEDT to update investors on the Company's technology, including the clinical program for Progenza™. Register here: https://us02web.zoom.us/webinar/register/WN_QdON4FErR3Woy4dxASFnZQ